|
Romiplostim This page contains brief information about romiplostim and a collection of links to more information from the National Cancer Institute (NCI) and the Food and Drug Administration (FDA). | US Brand Name(s): |  | Nplate | | | | FDA Approved: | | Yes |
Romiplostim is approved by the Food and Drug Administration (FDA) to treat thrombocytopenia (lower-than-normal number of cells in the blood that help blood clots to form). It is used in patients with chronic immune thrombocytopenic purpura (ITP), a condition in which these blood-clotting cells are destroyed by the immune system. This condition is also called idiopathic thrombocytopenic purpura. Romiplostim is used in certain patients with ITP who have not gotten better with corticosteroids or immunoglobulins, or with surgery to remove the spleen.
Information from the FDA
FDA Approval for Romiplostim - Information from the FDA about the approval of this drug and the clinical trials that led to the approval.
Information from the NCIDefinition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug. Clinical TrialsClinical Trials for Romiplostim - Check for trials from NCI's PDQ Cancer Clinical Trials Registry now accepting patients.
Important: The drug information on this Web page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
Back to Top |
